Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Vantia Ltd |
---|---|
Information provided by: | Vantia Ltd |
ClinicalTrials.gov Identifier: | NCT00769964 |
This is a first-in-human study of VA111913 TS, a new chemical entity being developed for the treatment of dysmenorrhea. This study is designed to investigate determine the safety, tolerability and pharmacokinetics of VA111913 TS after single and multiple doses in healthy non-pregnant female volunteers of child bearing age.
Condition | Intervention | Phase |
---|---|---|
Dysmenorrhea |
Drug: VA111913 TS / placebo |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Safety Study |
Official Title: | A First in Human Study Consisting of a Two-Part, Double-Blind, Placebo-Controlled, Escalating Single and Multiple Dose Study of VA111913 TS in Adult Non-Pregnant Women Volunteers With a Single Dose, Open, Fed vs. Fasting Crossover Phase |
Estimated Enrollment: | 121 |
Study Start Date: | September 2008 |
Estimated Study Completion Date: | March 2009 |
Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
VA111913 TS is a selective V1a-receptor antagonist. The hypothesised mechanism of action of a V1a receptor antagonist in dysmenorrhea has been described in literature. Contractions of the uterine muscle are required for normal menstruation. Women with dysmenorrhea have increased uterine myometrial tone and contractions and decreased blood flow to the uterus. These abnormalities have been shown to lead to the pain experienced in dysmenorrhea. Thus, if a drug is able to reduce the hyperreactivity of the uterus to physiological levels then the pain experienced in dysmenorrhea may be controlled. In humans, vasopressin, via the V1a receptor, is able to potently induce contractions in both uterine smooth muscle and uterine blood vessels. Thus, a V1a receptor antagonist will potentially inhibit these contractions and in turn reduce the pain experienced in dysmenorrhea.
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Contact: Volunteer Recruitment Manager | +44 1800 277477 |
United Kingdom | |
Charles River Clinical Services | Recruiting |
Edinburgh, United Kingdom, EH33 2NE | |
Principal Investigator: Acting Medical Director |
Responsible Party: | Charles River Clinical Services ( Acting Medical Director ) |
Study ID Numbers: | 913-001 |
Study First Received: | October 8, 2008 |
Last Updated: | October 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00769964 History of Changes |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Healthy (Dysmenorrhea) |
Signs and Symptoms Pelvic Pain Menstruation Disturbances |
Dysmenorrhea Pain Healthy |
Signs and Symptoms Pelvic Pain Pathologic Processes |
Menstruation Disturbances Dysmenorrhea Pain |